Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

INTRODUCTION: The standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by consolidation durvalumab as shown in the PACIFIC trial. The purpose of this study is to evaluate clinical outcomes and toxicities regarding the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghetti, Paolo, Volpi, Giulia, Facheris, Giorgio, Cossali, Gianluca, Mataj, Eneida, La Mattina, Salvatore, Singh, Navdeep, Imbrescia, Jessica, Bonù, Marco Lorenzo, Tomasini, Davide, Vitali, Paola, Greco, Diana, Bezzi, Michela, Melotti, Flavia, Benvenuti, Mauro, Borghesi, Andrea, Grisanti, Salvatore, Buglione di Monale e Bastia, Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352832/
https://www.ncbi.nlm.nih.gov/pubmed/37469420
http://dx.doi.org/10.3389/fonc.2023.1208204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352832/
https://www.ncbi.nlm.nih.gov/pubmed/37469420
http://dx.doi.org/10.3389/fonc.2023.1208204

Ejemplares similares